Payment overview · 2025
General Payments
$219.67
12 reported records · 9 companies
Healthcare provider profile · identity verified
Allison Maxwell Barnes, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · GRIFFIN, GA · NPI 1407247877
Verified facts
What the public records show
CMS Open Payments records show Allison Maxwell Barnes, NP-C received $219.67 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.75 | 29.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.18 | 14.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.86 | 10.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.78 | 9.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.72 | 8.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.99 | 7.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.44 | 7.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.40 | 7.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.55 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.67 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 296 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 79 |
| Omeprazole | Omeprazole | 257 | 85 |
| Gabapentin | Gabapentin | 205 | 69 |
| Lisinopril | Lisinopril | 201 | 66 |
| Tramadol Hcl | Tramadol Hcl | 201 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 68 |
| Metformin Hcl | Metformin Hcl | 178 | 51 |
| Simvastatin | Simvastatin | 149 | 40 |
| Sertraline Hcl | Sertraline Hcl | 144 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 43 |
| Alprazolam | Alprazolam | 138 | 33 |
| Losartan Potassium | Losartan Potassium | 137 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 46 |
| Furosemide | Furosemide | 128 | 47 |
| Prednisone | Prednisone | 123 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 33 |
| Mounjaro | Tirzepatide | 108 | 18 |
| Potassium Chloride | Potassium Chloride | 102 | 38 |
| Allopurinol | Allopurinol | 87 | 30 |
| Clonazepam | Clonazepam | 87 | 19 |
| Lorazepam | Lorazepam | 87 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 33 |
| Ozempic | Semaglutide | 85 | 16 |
| Ezetimibe | Ezetimibe | 83 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 30 |
| Famotidine | Famotidine | 79 | 29 |
| Metformin Hcl Er | Metformin Hcl | 77 | 29 |
| Montelukast Sodium | Montelukast Sodium | 77 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 50 |
| Trazodone Hcl | Trazodone Hcl | 75 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 24 |
| Eliquis | Apixaban | 70 | 22 |
| Pregabalin | Pregabalin | 65 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 17 |
| Carvedilol | Carvedilol | 62 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 27 |
| Glipizide Er | Glipizide | 58 | 16 |
| Azithromycin | Azithromycin | 57 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 19 |
| Atenolol | Atenolol | 50 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 17 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Cefuroxime | Cefuroxime Axetil | 44 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 14 |
| Glimepiride | Glimepiride | 40 | 16 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 37 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Jardiance | Empagliflozin | 34 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Colchicine | Colchicine | 33 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 25 |
| Finasteride | Finasteride | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 14 |
| Nystatin | Nystatin | 32 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Fluconazole | Fluconazole | 25 | 21 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 16 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 14 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Ketoconazole | Ketoconazole | 17 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Temazepam | Temazepam | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $219.67 · 12 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, ELIQUIS, General - Pain Management, MINIMED 780G, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error